Who is suitable for Pemafibrate? Indications and contraindications for populations
Pemafibrate is suitable for specific patients with dyslipidemia, but there are clear contraindications for the population. The following provides a detailed explanation of the applicable conditions and limitations from the perspectives of indications and contraindications.
1. Indicative population
Mainly used to treat primary hyperlipidemia in adults, especially in patients with elevated triglycerides (TG ≥ 150mg/dL). When combining statins with mixed hyperlipidemia (accompanied by elevated LDL-C), the risk of myopathy should be rigorously evaluated.
2. Absolute taboo group
Patients with severe renal insufficiency (eGFR<30ml/min) are contraindicated as the drug may accumulate and cause adverse reactions. Patients with active liver disease or unexplained persistent elevation of transaminase should avoid using it, as it may worsen liver damage.
3. Relatively taboo population
Patients with moderate renal impairment (eGFR30-59ml/min) need to reduce their dosage by 50%. Pregnant women are prohibited from using it, as animal experiments have shown a risk of embryonic toxicity. Breastfeeding women should suspend medication or stop breastfeeding.
4. Caution should be exercised when using the target audience
Elderly patients (≥ 65 years old) should start with a small dose as it may be accompanied by renal dysfunction. Those who use anticoagulants or CYP2C8 inhibitors simultaneously need to be closely monitored as it may increase the risk of bleeding or drug accumulation.
5. Special monitoring requirements
All users are required to undergo regular liver function tests (once a month for the first 3 months) and creatine kinase levels. Diabetes patients need to strengthen blood glucose monitoring, which may affect insulin sensitivity.
6. Precautions for special populations
Patients with renal insufficiency (eGFR<30ml/min) are prohibited from using it, and those with moderate renal impairment need to reduce their dosage by 50%. Patients with abnormal liver function should regularly monitor ALT/AST and discontinue medication if the condition persists.
7. Diet and lifestyle
A high-fat diet may affect drug absorption, and it is recommended to take it 1 hour before meals. Alcohol may increase the burden on the liver, and alcohol consumption should be limited during treatment.
Disclaimer：《Who is suitable for Pemafibrate? Indications and contraindications for populations》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！